BND-35

ILT3 is a key protein expressed by suppressive myeloid cells, including tumor-associated macrophages, myeloid-derived suppressive cells and tolerogenic dendritic cells. ILT3 enhances the activity of suppressive myeloid cells and decreases T-cell function, leading to an immuno-suppressive tumor microenvironment, which is known to limit the potency of different therapeutic interventions.
BND-35 has been shown in preclinical studies to restore T cell activity inhibited by different suppressive myeloid cells and to enhance anti-tumor activity in various models. The antibody is in advanced pre-clinical development stages.